Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.02%
#3 Fabric Protocol Fabric Protocol +30.68%
#4 Nockchain Nockchain +19.84%
#5 Cysic Cysic +19.17%
#6 Bedrock Bedrock +18.72%
#7 Perle Perle +11.77%
#8 The Black Bull The Black Bull +10.40%
#9 FOLKS FOLKS +7.85%
#10 Epic Chain Epic Chain +7.11%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Amniotics AB (publ) Amniotics AB (publ)

Amniotics AB (publ)

AMNI
Rang in aandelen #37511
Amniotics AB (publ) specializes in the creation, manufacturing, and... Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Aandeelprijs
$0.00060315
Laatst gesynchroniseerd: 2024-09-27
Marktkapitalisatie
$1.65M
Verandering (1 dag)
19.64%
Verandering (1 jaar)
0.00%
Land
SE
Handel Amniotics AB (publ) (AMNI)

Categorie

Healthcare
Winst voor Amniotics AB (publ) (AMNI)
Winst in Dec 2023 TTM: $-3.09M
Volgens de meest recente financiële verslagen van Amniotics AB (publ) bedraagt de huidige winst van het bedrijf $-3.09M. In 2022 behaalde het bedrijf een winst van $-4.61M, een stijging ten opzichte van de winst van 2021, die $-5.92M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Amniotics AB (publ) van 2018 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-3.09M 0.85%
2023 $-3.06M -33.59%
2022 $-4.61M -22.23%
2021 $-5.92M 57.96%
2020 $-3.75M 235.76%
2019 $-1.12M 45.50%
2018 $-767.77K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -171,033.57%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -63,310.98%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -97,500.51%
BE